# Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN

> **NCT02596074** · PHASE2 · COMPLETED · sponsor: **Maruho Co., Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Usual Type Vulval Intraepithelial Neoplasia (uVIN)

## Interventions

- **DRUG:** Omiganan (CLS001) topical gel
- **DRUG:** Vehicle topical gel

## Key facts

- **NCT ID:** NCT02596074
- **Lead sponsor:** Maruho Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2017-03-07
- **Final completion:** 2017-07-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02596074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02596074, "Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02596074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*